Editorial: Osteoporosis and adipokines: the potential for future treatment

Abstract

Osteoporosis is a major health concern, particularly in older people. It is characterized by decreased bone density and a higher fracture risk. Globally, it affects 35.3% of women and 12.5% of men (1). Recent studies have concentrated on the role of adipokines in bone metabolism control and osteoporosis progression. Adipokines are signaling substances produced by adipose tissue. Leptin, resistin, chemerin, visfatin, and other proteins have been shown to alter bone metabolism, making them possible targets for future osteoporosis treatments (2–4).